Day: January 27, 2022

Data to be presented suggests ACER-001 could represent a potential alternative to sodium and glycerol phenylbutyrate for treatment of UCDs NEWTON, Mass. and GENEVA, Jan. 27, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced the acceptance of four ACER-001 abstracts for poster presentations at the upcoming Society for Inherited Metabolic Disorders (SIMD) Annual Meeting on April 10-13, 2022 in Orlando, Florida, and the Genetic Metabolic Dieticians International (GMDI) Conference on May 4-7, 2022, in Las Vegas, Nevada. The ACER-001 New Drug Application (NDA) for urea cycle disorders (UCDs) is currently under U.S. Food and Drug Administration (FDA) review with a Prescription Drug User Fee Act (PDUFA)...

McKeon Has Over 15 Years of Experience in Brand Marketing and is One of Vital Farms’ Most Tenured Marketing Leaders AUSTIN, Texas, Jan. 27, 2022 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today announced the appointment of Kathryn McKeon to Chief Marketing Officer (CMO) effective January 27, 2022. McKeon has over 15 years of experience in brand marketing, with a specific focus on building global and emerging consumer food brands. As CMO, McKeon will oversee the Brand, Content, Community Management, Shopper Marketing, Consumer Insights, Communications and Creative Design marketing functions. McKeon joined Vital Farms in 2016 as one of the first marketing leaders. In her more than five years with the company, she has served in several marketing...

NORTH BILLERICA, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC) to advance artificial intelligence (AI)-enabled imaging biomarkers in prostate cancer. The PCCTC is a premier multicenter clinical research organization specializing in cutting-edge prostate cancer research recognized for its culture of transparent project co-development between investigators, research sites and industry partners. The group’s distinguished investigators work together on a single mission: to design, implement and complete hypothesis-driven trials in prostate cancer, translating scientific discoveries into improved standards of care. Lantheus’ prostate cancer...

-MeiraGTx Receives $30 Million Cash Milestone Payment -MeiraGTx, in Collaboration with Janssen Pharmaceuticals, Inc., is Now Dosing Patients in the Phase 3 Lumeos Clinical Trial in X-linked Retinitis Pigmentosa -MeiraGTx Remains Eligible for Further Development and Commercial Milestones Related to botaretigene sparoparvovec (AAV-RPGR), as well as for AAV-CNGB3 and AAV-CNGA3 LONDON and NEW YORK, Jan. 27, 2022 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has received a $30 million payment from Janssen Pharmaceuticals, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, for a clinical milestone in the Phase 3 Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy for the...

TORONTO, Jan. 27, 2022 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE, TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, today announced that the Annual Meeting of its Shareholders will be held on Thursday, April 28, 2022 at 9:30 a.m. EDT in a virtual format due to the ongoing public health concerns related to the COVID-19 pandemic. Celestica also announced that it has set Friday, March 11, 2022 as the record date for determining shareholders of the company who are entitled to receive notice of, and to vote at, the meeting. This year, Celestica will be using the notice-and-access method for delivering the company’s proxy statement and related materials to shareholders eligible to participate at the meeting. Shareholders should expect to receive a notice-and-access...

NEW YORK and CHICAGO, Jan. 27, 2022 (GLOBE NEWSWIRE) — ESPN Enterprises, Inc. (“ESPN”) and Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today announced a multi-year renewal of its relationship that builds upon the digital integrations powering the partnership, with a significant focus on linear and addressable media. As the Official Ticketing Partner of ESPN, Vivid Seats will continue to provide ESPN users and sports fans across the country with easy access to one of the deepest and broadest selections of tickets for sporting events. Since 2017, ESPN and Vivid Seats have worked together to integrate a seamless ticket-buying experience from Vivid Seats throughout...

AUSTIN, Texas, Jan. 27, 2022 (GLOBE NEWSWIRE) — Chuy’s Holdings, Inc. (NASDAQ: CHUY) today announced that it will host a conference call to discuss fourth quarter and fiscal year 2021 financial results on Thursday, February 17, 2022 at 5:00 PM Eastern Time. A press release with fourth quarter and fiscal year 2021 financial results will be issued that same day after the market close. Hosting the call will be Steve Hislop, President and Chief Executive Officer, and Jon Howie, Vice President and Chief Financial Officer. The conference call can be accessed live over the phone by dialing 323-794-2551. A replay will be available after the call and can be accessed by dialing 412-317-6671; the passcode is 5169613. The replay will be available until Thursday, February 24, 2022. The conference call will also be webcast live from the Company’s...

22nd Consecutive Year of Earnings Improvement SUFFOLK, Va., Jan. 27, 2022 (GLOBE NEWSWIRE) — TowneBank (the “Company” or “Towne”) (Nasdaq: TOWN) today reported financial results for the full year and the fourth quarter ended December 31, 2021. For the year ended December 31, 2021, earnings were $215.38 million, or $2.97 per diluted share, compared to $145.54 million, or $2.01 per diluted share for the year ended December 31, 2020. Earnings in the fourth quarter of 2021 were $40.18 million, or $0.55 per diluted share, compared to fourth quarter 2020 earnings of $50.08 million, or $0.69 per diluted share. “We were pleased with our performance for 2021, highlighted by our 22nd year of increased earnings. We achieved record financial results with total revenues surpassing $680 million for the year, which...

Execution across an array of data-driven solutions earns EXL a place in the report’s Winners Circle NEW YORK, Jan. 27, 2022 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a leading global analytics and digital solutions company, today announced that it has been named a top provider of data and analytics solutions in HFS Research’s 2021 OneOffice™ Services Top 10 for Data and Decisions. HFS’ OneOffice Services research assesses the digital transformation capabilities of service providers in three areas: native automation, data and decisions, and people and process change. In each Top 10 Report, HFS analysts assess and rate provider capabilities across execution, innovation and voice of the customer criteria. As a top provider across all aspects of the HFS evaluation for Data and Decisions, EXL is positioned in the report’s “Winners Circle.” EXL...

NASHVILLE, Tenn., Jan. 27, 2022 (GLOBE NEWSWIRE) — Truxton Corporation, the parent company for Truxton Trust Company (“Truxton” or “the Bank”) and subsidiaries, announced its operating results for the quarter ended December 31, 2021. Fourth quarter net income attributable to common shareholders was $4.0 million or $1.39 earnings per diluted share compared to $3.5 million or $1.23 earnings per diluted share for the same quarter in 2020. Net income rose by 14% for the quarter compared to the fourth quarter of 2020 while fully diluted earnings per share rose by 13%. For the year ended December 31, 2021, net income increased by 30% to $14.5 million from $11.1 million in 2020. For the year ended December 31, 2021, earnings per diluted share rose to $5.02 from $3.90, an increase of 29% from 2020. “Truxton’s fourth quarter 2021 performance...